The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours.

[cutaneous mastocytosis]

Immunohistochemical expression of BAX was evaluated in 24 canine cutaneous mast cell tumours in order to verify the relationship of this expression to the histopathological grade of the lesions and its prognostic value for clinical outcome . BAX expression increased with higher histopathological grades (P =0 .0148 ; P <0 .05 between grades I and III ). Animals with high levels of BAX expression were 4 .25 times more likely to die from the disease and had shorter post-surgical survival times (P =0 .0009 ). These results suggest that alterations in BAX expression may be related to the aggressiveness of canine cutaneous mast cell tumours , indicating that immunohistochemical detection of BAX may be predictive of clinical outcome .

Diseases
Validation

Diseases presenting "high levels" symptom

22q11.2 deletion syndrome

adrenal incidentaloma

allergic bronchopulmonary aspergillosis

alpha-thalassemia

aromatase deficiency

cadasil

canavan disease

classical phenylketonuria

congenital adrenal hyperplasia

congenital toxoplasmosis

cutaneous mastocytosis

cystinuria

dentin dysplasia

dentinogenesis imperfecta

dracunculiasis

dystrophic epidermolysis bullosa

erythropoietic protoporphyria

gm1 gangliosidosis

hereditary cerebral hemorrhage with amyloidosis

holt-oram syndrome

homocystinuria without methylmalonic aciduria

kabuki syndrome

kallmann syndrome

liposarcoma

papillon-lefèvre syndrome

phenylketonuria

primary effusion lymphoma

primary hyperoxaluria type 1

scrub typhus

severe combined immunodeficiency

systemic capillary leak syndrome

triple a syndrome

von hippel-lindau disease

werner syndrome

wiskott-aldrich syndrome

wolf-hirschhorn syndrome

x-linked adrenoleukodystrophy

zellweger syndrome

You can validate or delete this automatically detected symptom